Please assess the completion status of the following clinical trial:

Trial Title: Ph I Study of Lithium During Whole Brain Radiotherapy For Patients With Brain Metastases

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histopathologically confirmed extracranial primary malignancy~  * Multiple (i.e., \> 3) brain metastases OR \< 3 metastases with at least 1 metastasis \> 4.0 cm in diameter~ * Not eligible for radiosurgery~* No requirement for immediate whole-brain radiotherapy~* No metastases to the midbrain or brainstem~Exclusion Criteria:~* Zubrod performance status 0-2~* Life expectancy ≥ 8 weeks~* Platelet count \> 100,000/mm\^3~* ANC \> 1,500/mm\^3~* Hemoglobin ≥ 10 g/dL~* BUN \< 25 mg/dL~* Creatinine \< 1.5 mg/dL~* Bilirubin \< 1.5 mg/dL~* ALT ≤ 2 times normal~* Sodium \> 136 mg/dL~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* Neurologically stable~  * No seizure disorders or seizures due to brain metastases~* No medical illnesses or psychiatric conditions that would preclude completion of study treatment~* No sensory neuropathy ≥ grade 2~* No bipolar disorder~* No thyroid disease~* No QTc interval prolongation~PRIOR CONCURRENT THERAPY:~* More than 2 weeks since prior and no concurrent chemotherapy~* At least 2 weeks since prior and no concurrent NSAIDs, angiotensin-converting enzyme inhibitors (e.g., enalapril or captopril), calcium channel blockers, diuretics, selective cyclooxygenase-2 inhibitors, acetazolamide, urea, xanthine, or alkalinizing agents (e.g., sodium bicarbonate)~* No prior radiotherapy to the head and neck area~* No prior radiosurgery~* No concurrent radiotherapy to other sites~* No concurrent anticonvulsants due to brain metastases~* No concurrent psychoactive drugs~* No concurrent thyroid medications~* No concurrent amifostine

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Therapeutic Intervention (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).